Quantitative HBeAg varies across the different phases of HBV infection, and can predict treatment outcome in the setting of HBV-reactivation driven by iatrogenic immunosuppression

Introduction and aim: Qualitative HBeAg is a marker of active HBV-replication and HBeAg-loss is an important clinical/therapeutic end-point. Here, we quantify HBeAg-levels in different phases of HBV-infection, their correlation with virological/biochemical markers and their role in predicting virological-response to anti-HBV therapy.